Nurse Practitioner with extensive experience in oncology, neurology, and clinical research. Committed to optimizing patient outcomes through excellence in clinical care and seamless transition to cutting edge therapies. Proven record of accomplishment in all stages of clinical trial conduct, from study design to publication.
Advanced Practice Nurse License NJ 26NJ00938200
Registered Nurse License NJ 26NO12237100
NPI# 1164076840
CDS # P00967600
Goldlust SA, Nabors LB, Mohile N, Benkers TL, Hsu SH, Silberman S, Singer, Rao M, Cappello L, Farmer G. Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma. J Clin Oncol 2017; 35 (suppl): abstr 2021.200020052018
Samuel A Goldlust, Samuel Singer, Lori A Cappello, Ahmad K Almekkawi, Kangman D Lee, Anthony C Ingenito, Brett E Lewis, Themba Nirenda, Hooman Azmi, George J Kaptain, Phase 1 Study of Concomitant Tumor Treating Fields and Temozolomide Chemoradition for Newly Diagnosed Glioblastoma, Neuro-Oncology Advances, 2024;, vdae129, https://doi.10.1093/noajnl/vdae129
Samuel A Goldlust, Louis B Nabors, Sigmund Hsu, Nimish Mohile, Paul J Duic, Tara Benkers, Samuel Singer, Mayank Rao, Lori Cappello, Sandra L Silberman, George Farmer, Phase 1 Trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma, Neuro-Oncology Advances, 2024, Volume 6, Issue 1, January-December 2024, vdae009, https://doi.org/10.1093/noajnl/vdae009